Quantcast

Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr Instagram
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
October 21, 2014, 08:29:53 AM

Login with username, password and session length


Members
Stats
  • Total Posts: 642857
  • Total Topics: 48905
  • Online Today: 221
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 5
Guests: 163
Total: 168

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Functional Glycomics in HIV Vaccine Design  (Read 1759 times)

0 Members and 1 Guest are viewing this topic.

Offline ichigo_kun

  • Member
  • Posts: 49
Functional Glycomics in HIV Vaccine Design
« on: April 17, 2012, 02:18:35 AM »
Functional Glycomics in HIV Vaccine Design
10 April 2012

http://www.vaccineorb.com/funding-opportunities/functional-glycomics-in-hiv-vaccine-design/

Halting the spread of HIV infection remains one of the highest research priorities of NIAID. Success in this effort will depend primarily on the identification and development of a safe and effective vaccine that prevents HIV transmission. Several vaccine candidates have been tested in human clinical studies, with one Phase III trial, RV144, showing modest efficacy in a community-based, randomized, multicenter, double-blind, placebo-controlled trial in Thailand. Additional analysis of this study identified six primary immune response variables. One variable, antibody binding levels to the HIV envelope (Env) glycoprotein first and second variable regions (V1V2), inversely correlated with HIV infection risk. While this study is encouraging, the need to identify new vaccine candidates with greater breadth, durability and efficacy remains a critical priority.

Approximately half of the molecular mass of HIV gp120 is comprised of N-linked glycans that shield the protein backbone. Several of these carbohydrate structures are critical for envelope folding, antigenicity, and immunogenicity. Determination of the identity and heterogeneity of glycans expressed on native gp120 trimers may be crucial for the development of new HIV vaccine candidates. Moreover, significant knowledge gaps remain in our understanding of broadly neutralizing antibody epitopes on the envelope spike that may serve as new targets for vaccination, as well as features that initiate broadly neutralizing antibody responses against the virus envelope glycoprotein.

Offline ichigo_kun

  • Member
  • Posts: 49
Re: Functional Glycomics in HIV Vaccine Design
« Reply #1 on: May 31, 2012, 08:06:33 PM »
Lancet Article Explores Efficacy Variable in RV144MHRP researchers detail risk correlation and early effect 5/31/2012 In the 30 May issue of The Lancet Infectious Diseases, MHRP researchers and collaborators provide important insights on behavioral and time variables that may have influenced the efficacy seen in the RV144 HIV vaccine study. In an accompanying editorial, José Esparza of the Bill and Melinda Gates Foundation notes that “The article by Robb et al is important, not only because it adds confidence to the original findings from the RV144 trial, but also because it identifies important variables to be considered when planning for and conducting additional trials to confirm and extend the results from RV144.”  In their post-hoc analysis, MHRP researchers correlate self-reported risk factors with vaccine efficacy at six month intervals. The RV144 trial enrolled mainly heterosexual people from a population with low prevalence of HIV. Participants classified as high or increasing risk at least once during follow-up were compared with those who maintained low-risk or medium-risk behavior. Interaction of risk status and acquisition efficacy was significant (p=0.01), with greater efficacy in low-risk individuals. In addition, researchers report that vaccine efficacy seemed to peak early—cumulative vaccine efficacy was estimated to be 60.5% (95% CI 22–80)—through the 12 months after initial vaccination, after which it declined quickly. This early, high protective immune response suggests an additional boost or other augmentation of immune response would improve efficacy for all risk categories. Smaller clinical studies are starting in Thailand this year that will add a second boost to the RV144 vaccine regimen in an effort to increase the duration of the early protective effect. In addition, results gleaned from a recent study published in the New England journal of Medicine on the case controlled correlates analysis provide new clues about the immune responses that may have played a role in protection. This information can be used to improve the RV144 vaccine regimen and also to help inform future clinical trial designs.  MHRP researcher Dr. Merlin Robb said that “although the RV144 trial did not produce a vaccine for public health today, the results provide an opportunity to understand the variables that can lead to better vaccines and how vaccines may target different populations.”
 http://www.hivresearch.org/news.php?NewsID=241

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.